LORVIQUA – (Lorlatinib)

Lorviqua is a cancer medicine used to treat adults with advanced non-small cell lung cancer that is ‘ALK-positive’, meaning that the cancer cells have certain changes that affect the gene responsible for a protein called ALK (alk-positive). of anaplastic lymphoma). Lorviqua is used on its own, when the disease has worsened despite treatment with other medicines in the same class known as ALK tyrosine kinase inhibitors, including alectinib, ceritinib and crizotinib.